Astria Therapeutics, Inc. (ATXS)

Astria Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	28.67	25.7	19.24	14.81	11.85	8.77
Research & Development	49.82	42.13	34.26	15.55	25.59	18.32
Other Operating Expenses	15.2	15.2	0	164.62	0	0
Operating Expenses	93.69	83.03	53.5	194.98	37.44	27.09
Operating Income	-93.69	-83.03	-53.5	-194.98	-37.44	-27.09
Other Expense / Income	-12.06	-10.14	-1.67	-0.06	-0.14	-0.8
Pretax Income	-81.63	-72.89	-51.83	-194.91	-37.3	-26.29
Net Income	-81.63	-72.89	-51.83	-194.91	-37.3	-26.29
Preferred Dividends	0	0	0	24.44	0	0
Net Income Common	-81.63	-72.89	-51.83	-219.35	-37.3	-26.29
Shares Outstanding (Basic)	52	30	15	9	3	2
Shares Outstanding (Diluted)	52	30	15	9	3	2
Shares Change	87.14%	106.03%	63.81%	191.81%	63.87%	121.55%
EPS (Basic)	-2.40	-2.42	-3.55	-24.58	-12.20	-14.10
EPS (Diluted)	-2.40	-2.42	-3.55	-24.58	-12.20	-14.10
Free Cash Flow	-74.31	-68.47	-43.62	-30.17	-32.52	-26.58
Free Cash Flow Per Share	-1.42	-2.27	-2.98	-3.38	-10.63	-14.24
EBITDA	-81.63	-72.89	-51.83	-194.91	-37.3	-26.29
EBIT	-81.63	-72.89	-51.83	-194.91	-37.3	-26.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).